Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. The company also focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer, as an alternative to bacillus calmetteguérin therapy. Aura Biosciences, Inc. was incorporated in 2009 and is based in Boston, Massachusetts.

Aura Biosciences Inc.

Aura Energy ( ($AU:AEE) ) has shared an announcement. Aura Energy has been granted an exploration permit for the Gräsmyråsen nr 1 tenement in Swede...

Aura Energy Expands Exploration Footprint in Sweden with New Tenement

Aura Energy ( ($AU:AEE) ) has shared an update. Aura Energy Limited has announced the issuance of 16,099,560 unquoted equity securities in the form...

Current Yield	N/A	Payout Ratio	N/A
Annual DPS	$0.00	Growth Streak	0 years
Ex-Dividend	Invalid Date	Pay Date	Invalid Date
Frequency	NA	Quarterly Est	$0.00

	A	B	C	D
1	Symbol	Price	Change	Volume
2	AURA	$5.44	+1.68%	160.52K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	AURA	$5.44	+1.7%	160.52K
3
4
5
6

AURA

AURA

Dividend Overview

Get Aura Biosciences Inc. Data in Excel

Get Aura Biosciences Inc. Data in Excel